BVS - CIK 0001665988
The table below shows Bioventus Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $74.67M | $38.80M | $15.34M | -$13.54M | $22.99M | $71.80M |
| Capital expenditure | $2.56M | $1.01M | $7.36M | $1.48M | $13.52M | $16.58M |
| Investing cash flow | -$3.25M | $22.96M | $15.81M | -$116.44M | -$283.76M | -$20.50M |
| Dividends paid | - | - | - | - | - | - |
Bioventus Inc. reported operating cash flow of $74.67M for fiscal year 2025. That is up 92.5% from $38.80M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow grew from $40.71M (FY 2019) to $74.67M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$62.14M | -$54.58M | -$26.65M | $62.08M | $273.37M | -$29.57M |